Short answer
Nautilus Biotechnology Inc (NAUT) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Nautilus Biotechnology’s Q3 2026 financial results for the quarter ended September 30, 2026.
Nautilus Biotechnology Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Nautilus Biotechnology’s Q3 2026 financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for reported financial performance and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $0.234M, primarily grants, versus $0 in Q3 2025, signaling an early commercialization stage
- Operating expenses $16.947M, up 10% year over year, driven by laboratory, professional services, salaries and benefits
- Net loss $15.636M, versus $13.574M, while nine-month loss reached $44.802M
- Cash, equivalents and investments $114.3M at September 30, 2026, with nine-month operating cash burn of $40.107M
- SEEDS consortium could provide up to $6M over four years, but funding remains subject to reduction, delay or termination
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nautilus Biotechnology Inc 8-K filings
Get the next NAUT 8-K as it lands
Follow NAUT for push alerts, or ask the research agent what this filing means.